Evidence map›Paper›PMID 42723405›Full record

Observational studyCanadian respiratory journal2026

Clinical Impact of HRCT UIP Pattern Among Patients With Idiopathic Pulmonary Fibrosis Undergoing Antifibrotic Treatment: A Multicenter Retrospective Observational Study.

Satoshi Nagaoka, Yu Hara, Hiroaki Fujii, Kota Murohashi, Ryo Nagasawa, Yoichi Tagami, Yusuke Saigusa, Tatsuji Enomoto, Yutaka Matsumoto, Makoto Masuda and 6 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Canadian respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Satoshi NagaokaDepartment of Pulmonology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama 236-0004, Kanagawa, Japan, yokohama-cu.ac.jp.ORCID https://orcid.org/0009-0002-9786-8668
Yu HaraDepartment of Pulmonology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama 236-0004, Kanagawa, Japan, yokohama-cu.ac.jp.ORCID https://orcid.org/0000-0002-2574-2516
Hiroaki FujiiDepartment of Pulmonology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama 236-0004, Kanagawa, Japan, yokohama-cu.ac.jp.ORCID https://orcid.org/0000-0003-2336-0394
Kota MurohashiDepartment of Pulmonology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama 236-0004, Kanagawa, Japan, yokohama-cu.ac.jp.
Ryo NagasawaDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi Kanazawa-ku, Yokohama 236-0051, Kanagawa, Japan.
Yoichi TagamiDepartment of Pulmonology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama 236-0004, Kanagawa, Japan, yokohama-cu.ac.jp.ORCID https://orcid.org/0000-0002-2134-1192
Yusuke SaigusaDepartment of Biostatistics, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa, Yokohama 236-0004, Japan, yokohama-cu.ac.jp.
Tatsuji EnomotoDepartment of Respiratory Medicine, Ofuna Chuo Hospital, 6-2-24 Ofuna, Kamakura 247-0056, Kanagawa, Japan, ofunachuohp.net.
Yutaka MatsumotoDepartment of Respiratory Medicine, Yamato Municipal Hospital, 8-3-6 Fukami-nishi, Yamato 242-8602, Kanagawa, Japan.
Makoto MasudaDepartment of Respiratory Medicine, Ofuna Chuo Hospital, 6-2-24 Ofuna, Kamakura 247-0056, Kanagawa, Japan, ofunachuohp.net.ORCID https://orcid.org/0000-0003-2575-4506
Nobuyuki HoritaDepartment of Pulmonology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama 236-0004, Kanagawa, Japan, yokohama-cu.ac.jp.ORCID https://orcid.org/0000-0002-8200-0340
Masaki YamamotoRespiratory Disease Center, Yokohama City University Medical Center, 4-57 Urafune-cho Minami-ku, Yokohama 232-0024, Kanagawa, Japan, yokohama-cu.ac.jp.ORCID https://orcid.org/0000-0001-7056-4192
Nobuaki KobayashiDepartment of Pulmonology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama 236-0004, Kanagawa, Japan, yokohama-cu.ac.jp.ORCID https://orcid.org/0000-0002-7064-320X
Takashi OguraDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi Kanazawa-ku, Yokohama 236-0051, Kanagawa, Japan.ORCID https://orcid.org/0000-0002-7445-270X
Takeshi KanekoDepartment of Pulmonology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama 236-0004, Kanagawa, Japan, yokohama-cu.ac.jp.
Makoto KudoRespiratory Disease Center, Yokohama City University Medical Center, 4-57 Urafune-cho Minami-ku, Yokohama 232-0024, Kanagawa, Japan, yokohama-cu.ac.jp.ORCID https://orcid.org/0000-0002-1837-0267

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIdiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease with a poor prognosis. Honeycombing on high-resolution computed tomography (HRCT) is a defining feature of the usual interstitial pneumonia (UIP) pattern and has traditionally been considered a marker of advanced disease. However, in the era of antifibrotic treatment (AFT), the prognostic significance of the UIP pattern in IPF remains uncertain. This study aimed to evaluate the association between HRCT UIP pattern and long-term prognosis in patients with IPF receiving AFT.

methodsThis retrospective multicenter study investigated consecutive patients with IPF who initiated AFT between 2009 and 2019 at seven institutions in Japan. HRCT patterns were classified as UIP or non-UIP by multidisciplinary assessment. The primary outcome was IPF-related events, defined as IPF-related death or first acute exacerbation (AE) after initiating AFT. Event-free survival was analyzed using Kaplan-Meier methods with stratification by gender-age-physiology (GAP) stage. Propensity score matching (PSM) was performed to adjust for age, sex, GAP score, and antifibrotic agent.

resultsOf the 139 patients included, 99 had a UIP pattern, and 40 had a non-UIP pattern. In the overall cohort, event-free survival did not differ significantly. Stratified analyses showed no significant survival difference between UIP and non-UIP patterns among GAP Stage I patients (median survival time [MST]: 2050 vs. 1104 days; p = 0.90). Similarly, among patients with GAP Stages II-III, MST did not differ significantly. After PSM, 34 matched pairs were analyzed, and no significant differences in event-free survival were observed between UIP and non-UIP patterns.

conclusionsIn patients with IPF treated with AFT, the radiological UIP pattern on HRCT was not independently associated with long-term prognosis. Multidimensional risk assessment incorporating physiological impairment and disease behavior may provide more accurate prognostic stratification in treated UIP populations.

Indexed as

Antifibrotic AgentsIdiopathic Pulmonary FibrosisTomography, X-Ray ComputedAgedDisease ProgressionFemaleHumansIndolesJapanMaleMiddle AgedPrognosisPyridonesRetrospective StudiesAntifibrotic AgentsIndolesnintedanibpirfenidonePyridonesantifibrotic treatmentidiopathic pulmonary fibrosisnintedanibpirfenidoneusual interstitial pneumonia

Identifiers

PMID42723405
PMCPMC13563058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.